ClinicalTrials.gg
TerminatedNCT03155932Updated Mar 24, 2022Results posted

Safety, Tolerability, and Efficacy of Etrasimod (APD334) in Participants With Primary Biliary Cholangitis

A Phase 2 interventional study of APD334 in Primary Biliary Cholangitis, sponsored by Arena Pharmaceuticals. Terminated at 9 sites in 3 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2022-03-24.

Sponsored by Arena Pharmaceuticals (part of Pfizer) · Phase 2, Interventional, and Treatment

Why this study was terminated
Sponsor decision

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
2
Allocation
Not applicable
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 83 studies in Liver Cirrhosis, Biliary with a site in United States — 11 open to participants now, 18 under way, 8 of them phase 3. Liver Cirrhosis, Biliary · United States.

Enrollment
62nd of 65
2 · median 46
Started
2017
with 7 others
Phase 2
34 of 83
2 open now
Registered
38th of 83
by date

Among the 83 studies in Liver Cirrhosis, Biliary with a site in United States, this one is the 62nd largest by enrollment of the 65 interventional ones that give a count, is one of 8 that started in 2017, is one of 34 in phase 2, and was the 38th registered.

Liver Cirrhosis, Biliary

214 studies on the registry are indexed under Liver Cirrhosis, Biliary; 48 are open to participants now.

Browse Liver Cirrhosis, Biliary studies →

Open to participants now

11 of the 83 studies in Liver Cirrhosis, Biliary with a site in United States are open now. Recruiting first, the newest first:

6 more — sign in →

All 11 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 34 Liver Cirrhosis, Biliary studies recruiting now, 16 (47%) set no upper age limit and 11 (32%) stop at 75 or younger; 3 take children under 18; 4 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 83 studies in Liver Cirrhosis, Biliary with a site in United States, or all of them as a file.
02

Study summary

The purpose of this open-label, pilot, proof of concept study is to evaluate the safety, tolerability, and efficacy of oral etrasimod (APD334) in participants with primary biliary cholangitis (PBC).

03

Conditions studied

  • Primary Biliary Cholangitis
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Males or females aged 18 to 80 years (inclusive) at the time of screening, with confirmed Primary Biliary Cholangitis (PBC) diagnosis based upon at least 2 of 3 criteria:

    • Anti-mitochondrial antibodies (AMA) titer >1:40 on immunofluorescence or M2 positive by enzyme-linked immunosorbent assay (ELISA) or positive PBC-specific antinuclear antibodies (anti-GP210 and/or anti-SP100)
    • Alkaline phosphatase (ALP) >1.5 x (ULN) for at least 6 months
    • Liver findings consistent with PBC
  • Use of ursodeoxycholic acid (UDCA) for at least 6 months prior to screening (stable dose for at least 3 months immediately prior to screening)
  • Participants must have ALP >1.5 x ULN but \<10 x ULN, (ALT) and aspartate aminotransferase (AST) \<5 x ULN, and total \<ULN, at all screening visits
  • AST, ALT, ALP, and total bilirubin must have 2 values at least 4 weeks apart that are within 20% of each other

Key Exclusion Criteria:

  • Chronic liver disease of a non-PBC etiology. However, PBC participants accompanied with primary Sjögren's syndrome (pSS) are eligible to be enrolled.
  • History or evidence of hepatic decompensation
  • Medical conditions that may cause non-hepatic increases in ALP (e.g., Paget's disease)
  • Clinically significant infections within 6 weeks prior to treatment start, or infection with virus anytime in the past
  • , immunomodulating, or agents within 30 days prior to treatment start
  • Treatment with obeticholic acid (OCA) within 30 days prior to Day 1

Note: Other protocol defined Inclusion/Exclusion criteria may apply

Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
2 participants (actual)

Study arms

  • Experimental
    APD334

    APD334 active treatment for 24 weeks.

    Drug: APD334

Interventions

  • DrugAPD334

    APD334 active treatment for 24 weeks.

    Also known as: etrasimod

06

What researchers measure

Primary outcomes

  1. Change in Serum Alkaline Phosphatase (ALP) Concentration

    Reduction in ALP concentration is a surrogate marker of slower disease progression.

    Time frame: Baseline, Week 24

  2. Number of Participants With Adverse Events

    Safety was assessed by monitoring adverse events and clinically relevant changes in vital signs and clinical laboratory results.

    Time frame: Up to Week 26

Secondary outcomes

  1. Change in Serum ALP Concentration

    Reduction in ALP concentration is a surrogate marker of slower disease progression.

    Time frame: Baseline, Week 12

  2. Pharmacokinetic Parameters of Etrasimod, and Its Metabolites

    Time frame: Up to Week 24

Other outcomes

  1. Exploratory - Change in Complete Blood Count

    Time frame: Baseline, Week 12, Week 24

  2. Exploratory - Change in Incidence of Fatigue as Assessed by Peripheral Biliary Cholangitis (PBC-40) Scale

    Time frame: Baseline, Week 12, Week 24

  3. Exploratory - Change in Incidence of Pruritus as Assessed by 5-Dimensions (5-D) Itch Scale

    Time frame: Baseline, Week 12, Week 24

  4. Exploratory - Change in Schirmer Test Outcome

    Time frame: Baseline, Week 12, Week 24

  5. Exploratory - Change in Tear Film Break-Up Time

    Time frame: Baseline, Week 12, Week 24

  6. Exploratory - Change in Concentration of Serum High Sensitivity C-Reactive Protein (hsCRP)

    Time frame: Baseline, Week 12, Week 24

  7. Exploratory - Change in Concentration of Serum Alanine Transaminase (ALT)

    Time frame: Baseline, Week 12, Week 24

  8. Exploratory - Change in Concentration of Serum Aspartate Transaminase (AST)

    Time frame: Baseline, Week 12, Week 24

  9. Exploratory - Change in Concentration of Serum Gamma-Glutamyl Transferase (GGT)

    Time frame: Baseline, Week 12, Week 24

  10. Exploratory - Change in Concentration of Serum C4

    Time frame: Baseline, Week 12, Week 24

  11. Exploratory - Change in Concentration of Serum Immunoglobulin

    Time frame: Baseline, Week 12, Week 24

  12. Exploratory - Change in Concentration of Serum GP73

    Time frame: Baseline, Week 12, Week 24

  13. Exploratory - Change in Concentration of Serum Anti-Mitochondrial Antibodies (AMA)

    Time frame: Baseline, Week 12, Week 24

  14. Exploratory - Change in Quality of Life

    Time frame: Baseline, Week 12, Week 24

07

Results

Posted Mar 24, 2022

Participant flow

Participant flow — Overall Study
MilestoneAPD334
Started2
Participants escalated to 2 mg dose of apd334 at week 12 to week 242
Completed2
Not completed0

Outcome measures

PrimaryChange in Serum Alkaline Phosphatase (ALP) Concentration

Reduction in ALP concentration is a surrogate marker of slower disease progression.

Time frame:
Baseline, Week 24

No measurements were reported for this outcome.

PrimaryNumber of Participants With Adverse Events

Safety was assessed by monitoring adverse events and clinically relevant changes in vital signs and clinical laboratory results.

Time frame:
Up to Week 26
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events
ParticipantsAPD334
Number of Participants With Adverse Events2
SecondaryChange in Serum ALP Concentration

Reduction in ALP concentration is a surrogate marker of slower disease progression.

Time frame:
Baseline, Week 12

No measurements were reported for this outcome.

SecondaryPharmacokinetic Parameters of Etrasimod, and Its Metabolites
Time frame:
Up to Week 24

No measurements were reported for this outcome.

Other pre-specifiedExploratory - Change in Complete Blood Count
Time frame:
Baseline, Week 12, Week 24

Results for this outcome have not been posted.

Other pre-specifiedExploratory - Change in Incidence of Fatigue as Assessed by Peripheral Biliary Cholangitis (PBC-40) Scale
Time frame:
Baseline, Week 12, Week 24

Results for this outcome have not been posted.

Other pre-specifiedExploratory - Change in Incidence of Pruritus as Assessed by 5-Dimensions (5-D) Itch Scale
Time frame:
Baseline, Week 12, Week 24

Results for this outcome have not been posted.

Other pre-specifiedExploratory - Change in Schirmer Test Outcome
Time frame:
Baseline, Week 12, Week 24

Results for this outcome have not been posted.

Other pre-specifiedExploratory - Change in Tear Film Break-Up Time
Time frame:
Baseline, Week 12, Week 24

Results for this outcome have not been posted.

Other pre-specifiedExploratory - Change in Concentration of Serum High Sensitivity C-Reactive Protein (hsCRP)
Time frame:
Baseline, Week 12, Week 24

Results for this outcome have not been posted.

Other pre-specifiedExploratory - Change in Concentration of Serum Alanine Transaminase (ALT)
Time frame:
Baseline, Week 12, Week 24

Results for this outcome have not been posted.

Other pre-specifiedExploratory - Change in Concentration of Serum Aspartate Transaminase (AST)
Time frame:
Baseline, Week 12, Week 24

Results for this outcome have not been posted.

Other pre-specifiedExploratory - Change in Concentration of Serum Gamma-Glutamyl Transferase (GGT)
Time frame:
Baseline, Week 12, Week 24

Results for this outcome have not been posted.

Other pre-specifiedExploratory - Change in Concentration of Serum C4
Time frame:
Baseline, Week 12, Week 24

Results for this outcome have not been posted.

Other pre-specifiedExploratory - Change in Concentration of Serum Immunoglobulin
Time frame:
Baseline, Week 12, Week 24

Results for this outcome have not been posted.

Other pre-specifiedExploratory - Change in Concentration of Serum GP73
Time frame:
Baseline, Week 12, Week 24

Results for this outcome have not been posted.

Other pre-specifiedExploratory - Change in Concentration of Serum Anti-Mitochondrial Antibodies (AMA)
Time frame:
Baseline, Week 12, Week 24

Results for this outcome have not been posted.

Other pre-specifiedExploratory - Change in Quality of Life
Time frame:
Baseline, Week 12, Week 24

Results for this outcome have not been posted.

Adverse events

Collected over Up to Week 26. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
APD3340/2 (0%)0/2 (0%)2/2 (100%)
Most frequent other events
Showing 10 of 13
Most frequent other events
EventAPD334
Skin rashSkin and subcutaneous tissue disorders1/2
Urinary tract infectionInfections and infestations1/2
Worsening right hip painMusculoskeletal and connective tissue disorders1/2
Elevated gamma-glutamyl transferase-worseningInvestigations1/2
Loose stoolsGastrointestinal disorders1/2
FatigueGeneral disorders1/2
Common cold - Upper respiratory tract infectionInfections and infestations1/2
Elevated alkaline phosphatase-worseningInvestigations1/2
Lower abdominal crampsGastrointestinal disorders1/2
PruritusSkin and subcutaneous tissue disorders1/2

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)APD334
<=18 years0
Between 18 and 65 years2
>=65 years0
Sex: Female, Male
Sex: Female, Male(Participants)APD334
FemaleNA
MaleNA
Race (NIH/OMB)
Race (NIH/OMB)(Participants)APD334
American Indian or Alaska NativeNA
AsianNA
Native Hawaiian or Other Pacific IslanderNA
Black or African AmericanNA
WhiteNA
More than one raceNA
Unknown or Not ReportedNA
08

Study locations

9 sites
  • Gastroenterology and Hepatology, UC Davis Medical Center
    Sacramento, California 95817, United States
  • Baylor College of Medicine
    Houston, Texas 77030, United States
  • Texas Liver Institute
    San Antonio, Texas 78215, United States
  • Swedish Medical Center
    Seattle, Washington 98104, United States
  • Royal Prince Alfred Hospital
    Camperdown, New South Wales 2050, Australia
  • Sunshine Coast University Hospital
    Birtinya, Queensland 4575, Australia
  • Alfred Health
    Melbourne, Victoria 3004, Australia
  • Auckland City Hospital
    Grafton, Auckland 1023, New Zealand
  • Christchurch Clinical Studies Trust
    Christchurch, 8011, New Zealand
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2017 to primary completion in Jan 2019, 13 months.

Results were first posted in Mar 2022, 3 years 1 month after primary completion. A results delay was requested in Jan 2020.

How these figures are worked out, and which studies are left out of them.

Registered
May 11, 2017
First posted
May 16, 2017
StartActual
Dec 29, 2017
Primary completionActual
Jan 31, 2019
CompletionActual
Jan 31, 2019
Results delay requested
Jan 30, 2020
Results first posted
Mar 24, 2022
Last update
Mar 24, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 24, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03155932
Responsible party
Sponsor
First posted
May 16, 2017
Start date
Dec 29, 2017
Primary completion
Jan 31, 2019
Completion
Jan 31, 2019
Results posted
Mar 24, 2022
Last update
Mar 24, 2022

Study contacts

Arena CT.gov Administrator
study director · Arena Pharmaceuticals

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Etrasimod

Start the discussion